XML 68 R62.htm IDEA: XBRL DOCUMENT v3.26.1
Earnings Per Share - Computations of Basic and Diluted Earnings Per Share (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Computation of Basic Earnings per Share        
Net income (loss) $ 22,911 $ 11,341 $ (18,495) $ 31,052
Weighted-average number of common shares outstanding 22,897 22,865 22,893 22,866
Basic earnings per share $ 1 $ 0.5 $ (0.81) $ 1.36
Computation of Diluted Earnings per Share        
Weighted-average number of common shares outstanding 22,897 22,865 22,893 22,866
Add weighted-average net shares related to unvested stock awards (under treasury stock method) [1] 19 2   2
Weighted-average shares applicable to diluted earnings 22,924 22,879 22,893 22,885
Diluted earnings per share $ 1 $ 0.5 $ (0.81) $ 1.36
Stock Option [Member]        
Computation of Diluted Earnings per Share        
Add weighted-average net shares from assumed exercise of options (under treasury stock method) [1],[2]   7   10
Stock Appreciation Rights (SARs) [Member]        
Computation of Diluted Earnings per Share        
Add weighted-average net shares from assumed exercise of options (under treasury stock method) [1],[2]   5   7
Performance Stock Award [Member]        
Computation of Diluted Earnings per Share        
Add weighted-average net shares from assumed exercise of options (under treasury stock method) [1] 8      
[1] For the six months ended June 30, 2026, potential common shares were excluded from the computation of diluted earnings per share because of their anti-dilutive effect due to the net loss for the first six months in 2026.
[2] Options/SARs to acquire 1,167,695 shares of the Company's common stock were excluded from the computation of dilutive earnings per share for the three months ended June 30, 2026. Options/SARs to acquire 1,205,183 and 1,209,553 shares of the Company's common stock were excluded from the computation of dilutive earnings per share for the three and six months ended June 30, 2025, respectively. The options/SARs' exercise prices were greater than the average market price for the Company's common stock and inclusion of the instruments would have had an antidilutive effect on the computations of the earnings per share.